Cargando…

Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction

Autoimmune destruction of pancreatic β cells underlies type 1 diabetes (T1D). To understand T cell-mediated immune effects on human pancreatic β cells, we combine β cell-specific expression of a model antigen, CD19, and anti-CD19 chimeric antigen receptor T (CAR-T) cells. Coculturing CD19-expressing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Haiting, Jeppesen, Jacob F., Jaenisch, Rudolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659530/ https://www.ncbi.nlm.nih.gov/pubmed/33205073 http://dx.doi.org/10.1016/j.xcrm.2020.100097

Ejemplares similares

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms
por: Talleur, Aimee C., et al.
Publicado: (2023)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
por: Zhang, Cheng, et al.
Publicado: (2020)

Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
por: Li, Xin, et al.
Publicado: (2021)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia
por: Jin, Chun-Hui, et al.
Publicado: (2018)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
por: Grain, Audrey, et al.
Publicado: (2023)

Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
por: Lontos, Konstantinos, et al.
Publicado: (2022)

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
por: Yang, Fei, et al.
Publicado: (2019)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells
por: Zhang, Yuanyuan, et al.
Publicado: (2023)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
por: Noh, Kyung-Eun, et al.
Publicado: (2021)

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
por: Schultz, Liora, et al.
Publicado: (2020)

T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma
por: Wang, Jiachen, et al.
Publicado: (2022)

Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells
por: Mika, Thomas, et al.
Publicado: (2020)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Antigen glycosylation regulates efficacy of CAR T cells targeting CD19
por: Heard, Amanda, et al.
Publicado: (2022)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
por: Pfeiffer, Anett, et al.
Publicado: (2018)

Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma
por: Brudno, Jennifer N., et al.
Publicado: (2020)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells
por: Lobner, Elisabeth, et al.
Publicado: (2020)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

Accumulation of synovial fluid CD19(+)CD24(hi)CD27(+) B cells was associated with bone destruction in rheumatoid arthritis
por: Guo, Xiaofeng, et al.
Publicado: (2020)

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
por: Zanetti, Samanta Romina, et al.
Publicado: (2022)

COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Development of a physiological insulin resistance model in human stem cell–derived adipocytes
por: Friesen, Max, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic studies of CD19 CAR T cell in human leukaemic xenograft models with dual‐modality imaging
por: Wu, Qiong, et al.
Publicado: (2021)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_me54h23cg9p1vrof1d54bk6ndj